Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
5
71%
Ph phase_4
1
14%
Ph phase_2
1
14%

Phase Distribution

0

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
5(71.4%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (14.3%)
Phase 35 (71.4%)
Phase 41 (14.3%)

Trials by Status

terminated114%
completed571%
unknown114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

NCT02279498
completedphase_4

EASY: Extended Access to Sollpura Over Years

NCT02823964
unknownphase_3

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

NCT03051490
terminatedphase_3

Phase III ALTU-135 CP Safety Trial

NCT00500084
completedphase_3

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02279498Phase 3

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Completed
NCT02823964Phase 4

EASY: Extended Access to Sollpura Over Years

Completed
NCT03051490Phase 3

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Unknown
NCT00500084Phase 3

Phase III ALTU-135 CP Safety Trial

Terminated
NCT00449878Phase 3

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Completed
NCT00449904Phase 3

Open-Label Phase III Long-Term Safety Trial of Liprotamase

Completed
NCT00095732Phase 2

Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7